Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 9Carcinoma, Non-Small-Cell Lung 7Rectal Neoplasms 6Colorectal Neoplasms 6Breast Neoplasms 6Neoplasms 5Glioblastoma 5Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Head and Neck Neoplasms 4Stomach Neoplasms 3Oligodendroglioma 3Mouth Neoplasms 3Lung Neoplasms 3Glioma 3Esophageal Neoplasms 3Astrocytoma 3Urinary Bladder Neoplasms 2Sarcoma 2Neoplasm Metastasis 2Meningioma 2Melanoma 2Gliosarcoma 2Glioma, Subependymal 2Fallopian Tube Neoplasms 2Ependymoma 2Carcinoma, Squamous Cell 2Carcinoma, Ovarian Epithelial 2Adenocarcinoma Of Esophagus 2Xerostomia 1

Interventions

Surgical Procedures, Operative 1Immunohistochemistry 1Ferrosoferric Oxide 1Erlotinib Hydrochloride 1Congresses as Topic 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Pancreatic Intraductal Neoplasms × Surgical Procedures, Operative × Clear all
NCT00482625 2014-10-16

Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Terminated
6 enrolled 8 charts
Gastrointestinal

Pancreatic Intraductal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡